6/21/2007 10:35:20 AM
TORONTO, ONTARIO--(MARKET WIRE)--Jun 21, 2007 -- Tissue Regeneration Therapeutics Inc. (TRT) announced today the exclusive US license of its HUCPVC (human umbilical cord perivascular cell) technology to Stem Cell Authority Ltd. (SCAL) for family stem cell banking. Under the terms of the agreement, SCAL gains US patent rights and manufacturing know-how in return for an upfront technology access fee and annual minimum royalties that will exceed CAD $20 M over the next four years. SCAL is currently offering HUCPVC collection and storage services to physicians for their patients across the US.
comments powered by